Претрага

Резултати

EGFR mutations in advanced non-small cell lung cancer patients in Serbia: 3 year-experience of central testing and gefitinib therapy response [2015]

Janković, Radmila ; Čavić, Milena ; Spasić, Jelena ; Krivokuća, Ana ; Ksenija Brotto ; Katarina Jovanović; Boljević, Ivana ; Tanić, Miljana ; Mališić, Emina ; ZARIĆ, BOJAN ;

PERIN, BRANISLAV ; Radosavljević, Davorin ; Radulović, Siniša ;

Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer - preliminary analysis of the PETACC-2-study [2006]

Carrato, A.; Kohne, C.; Bedenne, L.; Popov, Ivan ; Bouche, O.; Gaspar, E.; Rougier, P.; Schubert, U.; Biertz, F.; Becker, H.

851 Weekly paclitaxel (TAX) and capecitabine (CAP) for metastatic breast cancer (MBC) patients (PTS) previously treated with anthracycline-containing therapy - a phase I dose-finding study [2005]

Šušnjar, Snežana ; Bošnjak, Snežana ; Radulović, Siniša ; Stevanović, J.; Gajić-Dobrosavljević, Marija; Kreačić, Miroslav

Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck [2004]

Jeremic, B.; Milicic, B.; Dagovic, A. ; Vaskovic, Z.; Tadic, L.

FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. [2019]

Siefker-Radtke, Arlene O; Currie, Graeme; Abella, Esteban; Vaena, Daniel A; Kalebasty, Arash Rezazadeh; Curigliano, Giuseppe; Tupikowski, Krzysztof; Andric, Zoran G ; Lugowska, Iwona; Kelly, William Kevin

Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. [2019]

Hart, Lowell L; Andric, Zoran G ; ...; Radosavljevic, Davorin Z; Jovanovic, Dragana; ...; Samarzija, Miroslav; Zaric, Bojan ; ...; (broj, koautora 20)

Does the addition of chemotherapy (CT) to preoperative radiotherapy (preopRT) increase the pathological response in patients with resected rectal cancer: Report of the 22921 EORTC phase III trial. [2004]

Bosset, JF; Calais, Gilles; Mineur, Laurent; Maingon, Philippe; Radosevic-Jelic, Ljiljana M; Daban, Alain; Bardet, E; Beny, A; Collette, Laurence; Briffaux, A

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment [2022]

Garbe, Claus; ...; Kandolf-Sekulovic, Lidija O; ...; (broj, koautora 27)

Prognostic importance of objective response (OR) to chemotherapy for time to progression (TTP) and survival time (ST) in advanced non-small cell lung cancer (NSCLC): Analysis of individual patient data from platinum-based clinical trials in monocentric se [2005]

Radosavljevic, Davorin Z; Jelic, Svetislav B; Tomasevic, Zorica I ; Kezic, Iva

Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized double-blind safety and efficacy trial. [2010]

Rigas, James R; Schuster, Michael W; Orlov, Sergey V; Milovanovic, Branislav M; Prabhash, Kumar; Smith, Jeffrey T